208 related articles for article (PubMed ID: 29796823)
1. Investigation on the benefits of mycophenolate mofetil and therapeutic drug monitoring in the treatment of Japanese patients with lupus nephritis.
Katsuno T; Ozaki T; Ozeki T; Hachiya A; Kim H; Kato N; Ishimoto T; Kato S; Kosugi T; Tsuboi N; Mizuno M; Ito Y; Maruyama S
Clin Exp Nephrol; 2018 Dec; 22(6):1341-1350. PubMed ID: 29796823
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Drug Monitoring of Mycophenolic Acid in Lupus Nephritis: A Review of Current Literature.
Łuszczyńska P; Pawiński T
Ther Drug Monit; 2015 Dec; 37(6):711-7. PubMed ID: 26034895
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Lupus Nephritis Induction Treatments in a Hispanic Population: A Single-center Cohort Analysis.
Mejía-Vilet JM; Arreola-Guerra JM; Córdova-Sánchez BM; Morales-Buenrostro LE; Uribe-Uribe NO; Correa-Rotter R
J Rheumatol; 2015 Nov; 42(11):2082-91. PubMed ID: 26373566
[TBL] [Abstract][Full Text] [Related]
4. Multitarget therapy of mycophenolate mofetil and cyclosporine A for induction treatment of refractory lupus nephritis.
Jesus D; Rodrigues M; da Silva JAP; Inês L
Lupus; 2018 Jul; 27(8):1358-1362. PubMed ID: 29448882
[TBL] [Abstract][Full Text] [Related]
5. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis.
Rathi M; Goyal A; Jaryal A; Sharma A; Gupta PK; Ramachandran R; Kumar V; Kohli HS; Sakhuja V; Jha V; Gupta KL
Kidney Int; 2016 Jan; 89(1):235-42. PubMed ID: 26489028
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic drug monitoring of mycophenolate mofetil for the treatment of severely active lupus nephritis.
Kittanamongkolchai W; Rukrung C; Supasiri T; Lertjirachai I; Somparn P; Chariyavilaskul P; Avihingsanon Y
Lupus; 2013 Jun; 22(7):727-32. PubMed ID: 23651860
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Class IV Lupus Nephritis with Mycophenolate Mofetil Monotherapy.
Nawata T; Kubo M; Fujii S; Shiragami K; Ikegami T; Kobayashi S; Hisano S; Yano M
Intern Med; 2018 Jul; 57(14):2067-2070. PubMed ID: 29491296
[TBL] [Abstract][Full Text] [Related]
8. A Comparison Of Mycophenolate Mofetil And Cyclophosphamide As Lupus Nephritis Induction Therapy.
Gul H; Mushtaq MS; Salim B; Samreen S; Nasim A; Khan M
J Ayub Med Coll Abbottabad; 2020; 32(4):454-458. PubMed ID: 33225643
[TBL] [Abstract][Full Text] [Related]
9. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up.
Mok CC; Ying KY; Yim CW; Siu YP; Tong KH; To CH; Ng WL
Ann Rheum Dis; 2016 Jan; 75(1):30-6. PubMed ID: 25550339
[TBL] [Abstract][Full Text] [Related]
10. Surveillance for the use of mycophenolate mofetil for adult patients with lupus nephritis in Japan.
Yasuda S; Atsumi T; Shimamura S; Ono K; Hiromura K; Sada K; Mori M; Takei S; Kawaguchi Y; Tamura N; Takasaki Y
Mod Rheumatol; 2015; 25(6):854-7. PubMed ID: 25800636
[TBL] [Abstract][Full Text] [Related]
11. Mizoribine versus mycophenolate mofetil or intravenous cyclophosphamide for induction treatment of active lupus nephritis.
Feng X; Gu F; Chen W; Liu Y; Wei H; Liu L; Yin S; Da Z; Sun L
Chin Med J (Engl); 2014; 127(21):3718-23. PubMed ID: 25382325
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil or cyclophosphamide in indian patients with lupus nephritis: Which is better? A single-center experience.
Mendonca S; Gupta D; Ali S; Gupta P
Saudi J Kidney Dis Transpl; 2017; 28(5):1069-1077. PubMed ID: 28937065
[TBL] [Abstract][Full Text] [Related]
13. Outcome and predictors of renal survival in patients with lupus nephritis: Comparison between cyclophosphamide and mycophenolate mofetil.
Joo YB; Kang YM; Kim HA; Suh CH; Kim TJ; Park YW; Lee J; Lee JH; Yoo DH; Bae SC; Lee HS; Bang SY
Int J Rheum Dis; 2018 May; 21(5):1031-1039. PubMed ID: 29611341
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of mycophenolate mofetil and tacrolimus combination therapy in patients with lupus nephritis: a nationwide multicentre study.
Park DJ; Kang JH; Lee KE; Bae SC; Chung WT; Choe JY; Jung SY; Kim YS; Lee HS; Lee J; Lee YA; Park SH; Park YJ; Suh CH; Yoo DH; Lee SS
Clin Exp Rheumatol; 2019; 37(1):89-96. PubMed ID: 29998829
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis.
Choi CB; Won S; Bae SC
Lupus; 2018 May; 27(6):1007-1011. PubMed ID: 29448881
[TBL] [Abstract][Full Text] [Related]
16. The effectiveness and safety of mycophenolate mofetil in lupus nephritis.
Elyan M; Ballou S
Clin Rheumatol; 2009 Jul; 28(7):835-40. PubMed ID: 19319623
[TBL] [Abstract][Full Text] [Related]
17. Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial.
Kamanamool N; Ingsathit A; Rattanasiri S; Ngamjanyaporn P; Kasitanont N; Chawanasuntorapoj R; Pichaiwong W; Anutrakulchai S; Sangthawan P; Ophascharoensuk V; Avihingsanon Y; Sumethkul V
Lupus; 2018 Apr; 27(4):647-656. PubMed ID: 29105558
[TBL] [Abstract][Full Text] [Related]
18. Use of Glucuronidated Mycophenolic Acid Levels for Therapeutic Monitoring in Pediatric Lupus Nephritis Patients.
Hui-Yuen JS; Tran T; Taylor J; Truong K; Li X; Bermudez LM; Starr AJ; Eichenfield AH; Imundo LF; Askanase AD
J Clin Rheumatol; 2016 Mar; 22(2):75-9. PubMed ID: 26906299
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of mycophenolate mofetil in Japanese patients with systemic lupus erythematosus.
Kawazoe M; Kaneko K; Yamada Z; Masuoka S; Mizutani S; Yamada S; Shikano K; Sato H; Kaburaki M; Muraoka S; Kawai S; Nanki T
Clin Rheumatol; 2019 Jun; 38(6):1571-1578. PubMed ID: 30778862
[TBL] [Abstract][Full Text] [Related]
20. Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide.
Wang J; Hu W; Xie H; Zhang H; Chen H; Zeng C; Liu Z; Li L
Lupus; 2007; 16(9):707-12. PubMed ID: 17728363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
